文献速递胸部肿瘤头颈与中枢神经肿瘤

高剂量阿美替尼治疗未经治疗的EGFR突变非小细胞肺癌伴脑转移:ACHIEVE 2期非随机临床试验

High-Dose Aumolertinib for Untreated EGFR-Variant Non-Small Cell Lung Cancer With Brain Metastases: The ACHIEVE Phase 2 Nonrandomized Clinical Trial.
PubMed 文献 · JAMA Oncol · 2025-01-01

ACHIEVE为在中国10家中心开展的2期非随机临床试验,评估高剂量阿美替尼165 mg每日一次口服治疗未经治疗的EGFR突变非小细胞肺癌伴脑转移患者的疗效与安全性。共入组63例患者,主要终点12个月无进展生存率为62.1%(95%CI 48.7-73.0),中位无进展生存期20.5个月(95%CI 12.0-26.9),12个月颅内无进展生存率76.8%(95%CI 63.2-85.9)。

要点

  • 全分析集63例中,12个月无进展生存率为62.1%(95%CI 48.7-73.0),中位无进展生存期20.5个月(95%CI 12.0-26.9)。
  • 根据RECIST 1.1标准,全分析集系统性客观缓解率为56/63(88.9%),颅内客观缓解率为52/63(82.5%)。
  • 第2周期第1天血浆循环肿瘤DNA中EGFR变异清除与更长无进展生存期独立相关(HR 0.14,95%CI 0.04-0.47;P=.001)。

核心结论

  • 该非随机临床试验结果表明,高剂量阿美替尼与未经治疗的EGFR突变非小细胞肺癌伴脑转移患者的长期生存获益相关,且安全性可控。

研究设计与样本

  • 研究为在中国10家中心开展的2期非随机临床试验,于2021年7月6日至2022年8月31日入组未经治疗的EGFR突变转移性非小细胞肺癌伴脑转移患者。
  • 患者接受阿美替尼165 mg口服每日一次,直至疾病进展或出现不可接受的毒性反应。
  • 共63例患者纳入全分析集,其中49例至少有1个可测量脑病灶并纳入中枢神经系统可评估缓解集,数据截止日期为2024年10月10日。

主要发现

  • 全分析集中位随访时间为28.8个月(95%CI 27.0-29.8)。
  • 全分析集12个月无进展生存率为62.1%(95%CI 48.7-73.0),中位无进展生存期为20.5个月(95%CI 12.0-26.9),12个月颅内无进展生存率为76.8%(95%CI 63.2-85.9),中位颅内无进展生存期和总生存期均未达到。
  • 全分析集系统性客观缓解率为56/63(88.9%[95%CI 78.4-95.4]),颅内客观缓解率为52/63(82.5%[95%CI 70.9-90.9]);中枢神经系统可评估缓解集系统性客观缓解率为43/49(87.8%[95%CI 75.2-95.4]),颅内客观缓解率为42/49(85.7%[95%CI 72.8-94.1])。
  • 最常见的3级或4级治疗相关不良事件为血肌酸磷酸激酶升高(17例[27.0%]),未发生治疗相关死亡。
  • 第2周期第1天血浆循环肿瘤DNA中EGFR变异清除与更长无进展生存期独立相关(风险比0.14[95%CI 0.04-0.47];P=.001)。

关键数值与推荐

  • 主要终点为研究者根据实体瘤疗效评价标准(RECIST)1.1版评估的12个月无进展生存率。
  • 全分析集12个月无进展生存率为62.1%(95%CI 48.7-73.0),中位无进展生存期为20.5个月(95%CI 12.0-26.9)。
  • 全分析集12个月颅内无进展生存率为76.8%(95%CI 63.2-85.9)。
  • 全分析集系统性客观缓解率56/63(88.9%[95%CI 78.4-95.4]),颅内客观缓解率52/63(82.5%[95%CI 70.9-90.9])。
  • 第2周期第1天血浆循环肿瘤DNA中EGFR变异清除与更长无进展生存期独立相关(风险比0.14[95%CI 0.04-0.47];P=.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Central nervous system (CNS) metastases remain a significant challenge in the management of EGFR-variant non-small cell lung cancer (NSCLC). OBJECTIVE: To evaluate the activity and safety of high-dose aumolertinib in patients with untreated EGFR-variant NSCLC and brain metastases. DESIGN, SETTING, AND PARTICIPANTS: This was a phase 2 nonrandomized clinical trial conducted at 10 centers in China. Patients with untreated EGFR-variant metastatic NSCLC and brain metastases were enrolled between July 6, 2021, and August 31, 2022. The data cutoff date was October 10, 2024. INTERVENTIONS: Patients received aumolertinib, 165 mg, orally once daily until disease progression or unacceptable toxic effects. MAIN OUTCOMES AND MEASURES: The primary end point was 12-month progression-free survival (PFS) rate assessed by investigators according to the Response Evaluation Criteria In Solid Tumors (RECIST), version 1.1. RESULTS: A total of 63 patients (39 female [61.9%]; median age, 60 [range, 47-76] years) were enrolled (full analysis set), and 49 had at least 1 measurable brain lesion (CNS evaluable-for-response set). Median follow-up duration was 28.8 months (95% CI, 27.0-29.8). In the full analysis set, the 12-month PFS rate was 62.1% (95% CI, 48.7-73.0), the median PFS was 20.5 months (95% CI, 12.0-26.9), the 12-month intracranial PFS rate was 76.8% (95% CI, 63.2-85.9), and the median intracranial PFS and overall survival were not reached. Systemic and intracranial objective response rates per RECIST 1.1 were 56 of 63 (88.9% [95% CI, 78.4-95.4]) and 52 of 63 (82.5% [95% CI, 70.9-90.9]) in the full analysis set and 43 of 49 (87.8% [95% CI, 75.2-95.4]) and 42 of 49 (85.7% [95% CI, 72.8-94.1]) in the CNS evaluable-for-response set, respectively. The most common grade 3 or 4 treatment-related adverse event was increased blood creatine phosphokinase (17 participants [27.0%]). No treatment-related deaths occurred. EGFR variant clearance in plasma circulating tumor DNA at day 1 of cycle 2 was independently associated with longer PFS (hazard ratio, 0.14 [95% CI, 0.04-0.47]; P = .001). CONCLUSIONS AND RELEVANCE: The findings of this nonrandomized clinical trial suggest that high-dose aumolertinib is associated with long-term survival benefit in patients with untreated EGFR-variant NSCLC and brain metastases, with a manageable safety profile. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04808752.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Li H, Chen K, Gong L, et al. High-Dose Aumolertinib for Untreated EGFR-Variant Non-Small Cell Lung Cancer With Brain Metastases: The ACHIEVE Phase 2 Nonrandomized Clinical Trial. JAMA Oncol. 2025. PMID: 40569623. doi:10.1001/jamaoncol.2025.1779

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。